R. Dary Stone
Known title: DirectorCIK: 0001232173
Associated companies
Transaction History
| CUZ | ▲ Buy | Grant | 5,681 | $150K | 6/1/2026 | View on chart |
| CUZ | ▲ Buy | Grant | 4,186 | $105K | 6/1/2026 | View on chart |
| CUZ | ▲ Buy | Grant | 4,802 | $135K | 6/2/2025 | View on chart |
| CUZ | ▲ Buy | Grant | 3,558 | $95K | 6/2/2025 | View on chart |
| AIV | ▲ Buy | Grant | 24,499 | — | 1/29/2025 | View on chart |
| CUZ | ▲ Buy | Grant | 5,836 | $135K | 5/31/2024 | View on chart |
| CUZ | ▲ Buy | Grant | 4,324 | $95K | 5/31/2024 | View on chart |
| AIV | ▲ Buy | Grant | 30,184 | — | 1/31/2024 | View on chart |
| CUZ | ▲ Buy | Grant | 6,275 | $125K | 5/31/2023 | View on chart |
| CUZ | ▲ Buy | Grant | 4,624 | $87K | 5/31/2023 | View on chart |
| AIV | ▲ Buy | Grant | 26,596 | — | 2/1/2023 | View on chart |
| CUZ | ▲ Buy | Grant | 3,617 | $125K | 5/31/2022 | View on chart |
| CUZ | ▲ Buy | Grant | 2,666 | $87K | 5/31/2022 | View on chart |
| AIV | ▲ Buy | Grant | 12,355 | — | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
CUZ featured in value-stock comparison with NHI
A recent Yahoo Finance article compared Cousins Properties with National Health Investors as two candidates for value-focused portfolios. The piece highlights CUZ's elevated trailing P/E of 763.4 alongside a 6.47% dividend yield, framing the discussion around income versus valuation. With 11 analysts covering the stock and an average target of $33.64 against a 52-week range of $21.03 to $32.95, the comparison offers one snapshot for readers weighing these names side by side.
CUZ featured in value-stock comparison with NHI. A recent Yahoo Finance article compared Cousins Properties with National Health Investors as two candidates for value-focused portfolios. The piece highlights CUZ's elevated trailing P/E of 763.4 alongside a 6.47% dividend yield, framing the discussion around income versus valuation. With 11 analysts covering the stock and an average target of $33.64 against a 52-week range of $21.03 to $32.95, the comparison offers one snapshot for readers weighing these names side by side.